Re: Zenith Epigenetics Announces Collaboration with ... BMS = Bristol Myers Squibb = deep pockets

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Payzone

Rank: Mail Room [?]

Points: 198 [?]

Votes: 6 Score: 4.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigenetics Announces Collaboration with ... BMS = Bristol Myers Squibb = deep pockets

in response to

Re: Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

noretreat

posted on Oct 05, 2020 12:27PM

Nice to see Zenith partnering with a super major in the BP space.

BMS market cap = ~$133 Billion.

Acquired MyoKardia's cardio pipeline with a $13B buyout today.

https://endpts.com/bristol-myers-offers-a-big-premium-to-reel-in-myokardias-cardio-pipeline-with-a-13b-buyout/

just saying, BMS could take us out without breaking a sweat.

good luck

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply